The government alleges Labcorp and UHS delayed submission of orders for tests by Caris Life Sciences to enable improper billings to Medicare for those tests.

NEW YORK – Anbio Biotechnology filed this week a preliminary prospectus for an initial public offering on the Nasdaq exchange of 1.6 million shares at an anticipated offering price in the range of $5 ...

NEW YORK – After two years of decline in 2022 and 2023, the 360Dx Top 30 rebounded in 2024, rising 4 percent year over year.

Firms in the space advanced solutions to stratify sepsis patients and accelerated time-to-results to find out the cause of infections.

The firm received notice that it had failed to regain compliance with the Nasdaq's requirement to maintain a minimum $35 million market value of listed securities.

Rapid Health allegedly submitted false claims to Medicare for over-the-counter COVID-19 tests that were not provided to Medicare beneficiaries.

The Nova Scotia-based firm's Multiplo Rapid TP/HIV Test is used to detect antibodies to HIV 1/2 and syphilis in a finger prick blood sample.

Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for Roche's mass spec system, and features on Volition and Siemens Healthineers.

Foresight said Roche failed to bring its trade-secret causes of action within the three-year statute of limitations.

Consolidation within the industry also remained brisk as cost and reimbursement concerns provided acquisition opportunities for large national outfits.

The companies said they plan to explore a range of questions including the clinical implementation of the Alzheimer's disease biomarker phosphorylated tau 217.

NEW YORK — Laboratory-developed tests, FDA actions, the JP Morgan Healthcare Conference, and Roche — perhaps not surprisingly these subjects dominated the attention of 360Dx readers in 2024. Reader ...